- Company to invest Rs. 50 crores in India, its R&D facilities and its global affiliations by end of this financial year
- The product offers high quality Stents at affordable cost. With introduction of Yukon Choice PC from 1st week of May,2011the cost of treatment will be drastically reduced to 35-40% of which is prevailing now.
- YUKON Choice PC shall be sold globally with high focus on European and Asian markets.
- Manufacturing unit at Dehradun is spread across 5000 sq. feet
Translumina therapeutics, a joint Collaboration between one of the fastest growing Indian medical device company Advance Therapeutics with German heart Centre and Translumina GmbH announced the launch of “YUKON CHOICE PC” the First European Drug Eluting Stent which shall be manufactured in India for the treatment of coronary artery disease.
For the first time a proven drug eluting stent technology from Europe will be manufactured in India for the global markets .Currently, Indian patients have a choice of imported medicated Stent which are available at a price between Rs.90,000-1,00,000 depending on extent of studies carried out to prove its efficacy or safety. Since most of the patients in India pay from their pocket, these high prices of Stents prevented them to access the treatment of Angioplasty.
Translumina Therapeutics efforts with this collaboration shall provide Indian patients with a latest drug eluting Stent technology which is proven in large clinical trials in Europe as equal or better than the costly imported medicated Stent but shall be available at much affordable price.Morever,YUKON Choice PC also uses a patent technology of German Heart Centre, Munich which makes it more safer for patients in the long run.
On the occasion,Mr Gurmit Singh Chugh,MD , Translumina Therapeutics said,“It is a breakthrough development that could drastically reduce the cost of treatment by making Yukon choice PC more affordable for Indian Patients.It is the first time ever that a Drug eluting Stent is being manufactured in India for the global markets. As in other fields, Companies in west are taking note of the expertise available in India and are potentially exploring the possibility of taking advantage of low overheads.”
“The economical price shall also means high volumes as more patients shall be able to afford Angioplasty and these medicated stents become economical .If you see at the end, it is a win-win situation for us and the patients” he further added.
Dr. Julianda Mehili,Professor of Cardiology German Heart Centre said, “It is a significant landmark for Indian Physicians and patients as they will get the best technology at low prices .The Yukon Choice PC, with its unique microporous surface and biodegradable polymer releasing Sirolimus, is widely expected to improve the standard of care for many patients with Coronary Artery disease. We have done large scale trials to prove that this medicated stent is equal or marginally better than the currently premium products from the US based companies.”
More From This Section
This collaboration is the first effort in the world where a World class Hospital and 2 companies, one providing the technical and engineering support and other the manufacturing expertise, have come together to create a futuristic company to bring new technology at affordable cost.
Dr. Siegfried Einhellig , Chairman, Translumina GmbH, Germany said, “We are very pleased to unveil our European Drug Eluting Stent.Like China, I am sure that need of the hour is a good Indian product which is proven,accessible and economical and with YUKON Choice PC, we feel we are coming to the Indian market at just the right time Drug Eluting Stent becoming Polymer free in 3 months means that Cardiologists can treat variety of cases thus affording more patients with the opportunity to benefit from this innovative technology"
The product shall be available from 1st week of May, 2011 in Indian Markets gand shall be ready for Global launch as soon the CE mark is received. YUKON Choice PC is the first endeavour from this cooperation.The company plans to launch more innovative products Like drug eluting balloons,sheath less guiding Catheters ,guidwires and other consumables in this field of Interventional Cardiology .
About Us
Advance Therapeutics which is Indian arm of Translumina Therapeutics was started in 2004.The company was started by young professional, who were earlier involved in Senior management position in American multinational.The company was formed with an objective to source the best technologies from across the world and market them at an affordable cost in India. In a span of 5 years Advance therapeutics achieved a group turnover of 100 Crores.
In 2009,Adavance thearapeutics conceived an idea to diversify into manufacturing and thus Translumina Thearpeutics was created.It is formed with technical collaboration of German Heart Centre & Translumina GmbH, Germany... The company has set up an ultra modern manufacturing facility at Selaqui Dehradoon with World class Infrastructure including High quality clean rooms,Quality control and research labs with an objective to create a world class product.Few of the machines used for production and quality control are patented technologies of German heart centres and are not available in the open markets.The factory was regularly audited for quality controls by professional from German Heart Centre and Translumina
German Heart Centre:
At the time of its founding in 1974, the German Heart Centre Munich was the first heart centre in Germany. Since then, a lot of heart centres have followed in its footsteps. Since 1974, the overriding goal of the hospital management of the German Heart Centre Munich has been to provide outstanding medical care. German Heart Centre has written some landmark papers and publications on various topics related to cardiac problems.Their research as led Cardiologists around the world to form guidelines for the optimal treatment of the patients. German Heart Centre patented technology transfer to Translumina Therapeutics provides company with next generation biocompatible drug-eluting stents having advanced drug delivery systems. With this collaboration, we have developed unique coating technologies that utilize abluminal coating of drug & shellac resin for application on medical devices and drug delivery systems.